IL-17 Blockade in Psoriasis
- PMID: 27984714
- DOI: 10.1016/j.cell.2016.11.044
IL-17 Blockade in Psoriasis
Abstract
IL-17A both directly induces and synergizes with other cytokines to promote autoimmune tissue inflammation. Secukinumab and ixekizumab are monoclonal antibodies (mAb) that inhibit interleukin-17A. These two agents were recently approved for treatment of psoriasis, and secukinumab is also approved for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.
Copyright © 2016. Published by Elsevier Inc.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
